Intuitive SurgicalISRGEarnings & Financial Report
Intuitive Surgical, Inc. is an American biotechnology company that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System. The company is part of the Nasdaq-100, S&P 100 and S&P 500. As of 31 December 2021, Intuitive Surgical had an installed base of 6,730 da Vinci Surgical Systems, including 4,139 in the U.S.
ISRG Q4 2025 Key Financial Metrics
Revenue
$2.9B
Gross Profit
$1.9B
Operating Profit
$864.3M
Net Profit
$794.8M
Gross Margin
66.4%
Operating Margin
30.2%
Net Margin
27.7%
YoY Growth
18.8%
EPS
$2.19
Financial Flow
Intuitive Surgical Q4 2025 Financial Summary
Intuitive Surgical reported revenue of $2.9B for Q4 2025, with a net profit of $794.8M (27.7% margin). Cost of goods sold was $961.9M, operating expenses totaled $1.0B.
Key Financial Metrics
| Total Revenue | $2.9B |
|---|---|
| Net Profit | $794.8M |
| Gross Margin | 66.4% |
| Operating Margin | 30.2% |
| Report Period | Q4 2025 |
Intuitive Surgical Annual Revenue by Year
Intuitive Surgical annual revenue history includes year-by-year totals (for example, 2025 revenue was $10.1B).
| Year | Annual Revenue |
|---|---|
| 2025 | $10.1B |
| 2024 | $8.4B |
| 2023 | $7.1B |
| 2022 | $6.2B |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.89B | $2.01B | $2.04B | $2.41B | $2.25B | $2.44B | $2.51B | $2.87B |
| YoY Growth | 11.5% | 14.5% | 16.9% | 25.2% | 19.2% | 21.4% | 22.9% | 18.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $15.83B | $16.65B | $17.74B | $18.74B | $19.22B | $20.16B | $19.35B | $20.46B |
| Liabilities | $1.78B | $1.85B | $2.07B | $2.21B | $2.01B | $2.21B | $2.31B | $2.52B |
| Equity | $13.96B | $14.71B | $15.58B | $16.43B | $17.11B | $17.85B | $16.93B | $17.82B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $265.4M | $620.5M | $706.5M | $822.6M | $581.6M | $715.4M | $841.0M | $892.5M |
Other Health Care Companies
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
BAX
Baxter International
Revenue
$3.0B
Net Profit
$-1.1B
BDX
Becton Dickinson
Revenue
$5.3B
Net Profit
$382.0M
BSX
Boston Scientific
Revenue
$5.3B
Net Profit
$670.0M
DXCM
Dexcom
Revenue
$1.3B
Net Profit
$267.3M
EW
Edwards Lifesciences
Revenue
$1.6B
Net Profit
$291.1M
GEHC
GE HealthCare
Revenue
$5.7B
Net Profit
$588.0M
HOLX
Hologic
Revenue
$1.0B
Net Profit
$179.1M
IDXX
Idexx Laboratories
Revenue
$1.1B
Net Profit
$274.6M
PODD
Insulet Corporation
Revenue
$783.7M
Net Profit
$101.6M